Evaluation of Factors That Increase the Risk of Hepatotoxicity in Patients Using Palbociclib and Ribociclib

Authors : Serdar ATA, Filiz ARAZ, Timuçin ÇİL, Berna BOZKURT DUMAN

Pages : 224-228

Doi:10.36516/jocass.1279677

View : 108 | Download : 49

Publication Date : 2023-08-31

Article Type : Research Paper

Abstract :Aim: In patients with hormone receptor-positive and HER2-negative metastatic breast cancer, the use of CDK 4/6 inhibitors in combination with endocrine therapy have become a standard of care. Methods: This was a retrospective study involved patients over the age of 18 years, who had de novo metastatic or locally breast cancer progressed to the metastatic stage and were treated with ribociclib and/or palbociclib. Results: The mean age of a total of 73 patients included in the study was 57.0±10.3 years. Thirty-four insert ignore into journalissuearticles values(46.6%); patients were treated with palbociclib, 35 insert ignore into journalissuearticles values(47.9%); patients with ribociclib, 4 insert ignore into journalissuearticles values(5.5%); with palbociclib and ribociclib. Twenty-five insert ignore into journalissuearticles values(34.2%); of the patients developed any grade of hepatotoxicity, 12 insert ignore into journalissuearticles values(16.4%); of them was grade 2 hepatotoxicity. Of these patients, 11 insert ignore into journalissuearticles values(44%); received palbociclib, 13 insert ignore into journalissuearticles values(52%); received ribociclib, and 1 insert ignore into journalissuearticles values(4%); received palbociclib and ribociclib. In patients who were treated with palbociclib, 1 insert ignore into journalissuearticles values(2.9%); developed grade 3 hepatotoxicity and 1 insert ignore into journalissuearticles values(2.9%); developed grade 4 hepatotoxicity. Of those who received ribociclib, 3 insert ignore into journalissuearticles values(8.5%); developed grade 3 hepatotoxicity and 2 insert ignore into journalissuearticles values(5.7%); developed grade 4 hepatotoxicity. Conclusions: In conclusion, it can be stated that ribociclib is more toxic to the liver than palbociclib, since patients who received ribociclib and developed grade 3-4 hepatotoxicity had no disease that facilitates hepatotoxicity. We believe that more comprehensive studies are needed to determine the factors that facilitate hepatotoxicity such as liver metastasis and to select the drug accordingly will prevent patients from being devoid of this group of drugs and discontinuing their treatment due to toxicity.
Keywords : Ribociclib, palbociclib, breast cancer, hepatotoxicity

ORIGINAL ARTICLE URL